logo BDSP

Base documentaire

  1. Immunization programme against hepatitis B virus infection in italy : cost-effectiveness.

    Article, Communication - En anglais

    World Congress on Vaccines and Immunization. Istanbul, TUR, 1998/04/26.

    In Italy in the 1980s the extent of viral hepatitis B infection was on average about 11,000 symptomatic cases of acute viral hepatitis (AVH) per year (19/100,000 inhabitants).

    The prevalence of HBsAg carriers in the general population was about 3% and in pregnant women 2.4%. 64,000 people were affected by chronic viral hepatitis (CVH) or cirrhosis (prevalence rate 112/100,000) and 3400 by hepatocellular carcinoma (HCC) (prevalence rate 5.9/100,000).

    To reduce these HBV related pathologies in the Italian population, universal vaccination of newborn babies, 12-year old adolescents and high risk groups was implemented in 1991.

    The annual cost of this immunization is about 57 million 544 thousand USD : direct costs : 41 million 34 thousand USD : indirect costs : 16 million 510 thousand USD.

    Concerning the vaccination impact on HBV endemicity in Italy, we found a significant reduction of acute viral hepatitis incidence (4.2/100,000 in 1996 versus 19/100.000 in the'80s) and HBsAg carrier prevalence (0.9% in 1997 versus 3% in the'80s).

    As for the assistance and social cost of acute viral hepatitis occurring from 1991 to 1996 (17,608 cases) it was 238 million 908 thousand USD, while the cost for the same pathology in the years from 1985 to 1990 (35,614 cases) was 483 million 21 thousand USD.

    Thus, the saving during the years of the vaccination was evaluated in 244 million 308 thousand USD. (...)

    Mots-clés Pascal : Virus hépatite B, Orthohepadnavirus, Hepadnaviridae, Virus, Homme, Vaccin, Epidémiologie, Vaccination, Analyse coût efficacité, Programme sanitaire, Hépatite virale B, Virose, Infection, Appareil digestif pathologie, Foie pathologie, Italie, Europe, Europe Sud

    Mots-clés Pascal anglais : Hepatitis B virus, Orthohepadnavirus, Hepadnaviridae, Virus, Human, Vaccine, Epidemiology, Vaccination, Cost efficiency analysis, Sanitary program, Viral hepatitis B, Viral disease, Infection, Digestive diseases, Hepatic disease, Italy, Europe, Southern Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0287684

    Code Inist : 002B05A02. Création : 16/11/1999.